A 60-year-old woman came to us short of breath, with her legs swollen and her energy gone. Her heart was not pumping as it should, with an ejection fraction of 38 percent, well below normal. The picture was clear and familiar, and she was given the diagnosis it points to: heart failure with reduced ejection fraction. She was started on the full guideline-recommended treatment, the modern combination of drugs that helps the great majority of such patients feel and live better.
Six months later, she was not better. If anything, she was worse. Her symptoms had progressed despite a medication regimen that had been carefully optimised, pushed to the doses the guidelines call for. By every measure, she was receiving correct treatment for heart failure, and it was not working.
That failure to respond was the most important fact in her case, and it pointed to a problem hiding one level deeper than the label she had been given.
If you are on full, optimised treatment for heart failure and you keep getting worse rather than better, that is not a reason to simply push the same drugs harder. It is a reason to ask what is actually driving the heart failure.
The symptoms of heart failure are worth knowing, because they are common and treatable, but they describe a state rather than a cause:
- Breathlessness, especially on exertion and when lying flat at night
- Swelling in the legs, ankles or feet, as fluid backs up in the body
- Fatigue and a sharp drop in exercise tolerance, where ordinary effort becomes exhausting
- Waking suddenly breathless at night or needing extra pillows to sleep
- Rapid weight gain from fluid retention over days
What matters just as much are the warning signs that a heart failure is being driven by an unusual, specific cause, and the loudest of these is simple: it does not improve on treatment that should work. Other clues can include unusually thickened heart walls on the scan, intolerance of standard heart failure drugs, or seemingly unrelated problems like carpal tunnel syndrome appearing in the years beforehand.
What the first opinion concluded
Her first assessment came from cardiology, which diagnosed heart failure with reduced ejection fraction and set about optimising her therapy.
For most patients, this is exactly right. Heart failure is usually driven by common causes such as coronary disease or long-standing high blood pressure, and guideline therapy is genuinely life-saving in those cases.
But there is a conceptual trap buried in the word itself, and she had fallen into it. Heart failure is a syndrome, not a diagnosis. It is the final common pathway, the shared endpoint that many very different diseases arrive at when they damage the heart. The standard drugs treat the failing pump. They do not treat whatever is causing it to fail. If the underlying disease is something those drugs cannot touch, then optimising them simply means doing more of something that was never going to be enough.
The second opinion
She was referred to a cardiology tertiary centre for a medical second opinion, and rather than adjust her drugs again, they asked the question that had been skipped: why is this heart failing?
To answer it, they performed a myocardial biopsy, taking a tiny sample of the heart muscle itself to examine directly. The finding changed everything. She had AL amyloidosis. In this condition, abnormal proteins called light chains, produced by a disordered population of plasma cells in the bone marrow, build up and deposit in the tissues. In her case they had infiltrated the heart muscle, stiffening it and steadily wrecking its function. Her heart was not the disease. It was the place where a blood and bone-marrow disease happened to be doing its damage.
This reframing had immediate consequences. Because the root problem was a plasma cell disorder, she was referred onward to haematology-oncology, and treated with systemic chemotherapy aimed at shutting down the abnormal cells producing the toxic protein. After only two cycles her heart responded, and her ejection fraction began to recover. Treating the cause did what treating the syndrome never could.
Why this case matters
The principle is captured in a single sharp idea.
Heart failure is a syndrome, not a diagnosis. Behind every case there is a cause, and the only real question is whether anyone went looking for it.
Naming the syndrome can feel like an answer, and the standard treatment usually is one. But "heart failure" describes what the heart is doing, not why, and clear communication in healthcare means being honest about that distinction rather than letting the label stand in for an explanation. The single most useful trigger to go hunting for the cause is the one she showed: a patient who is correctly treated and still deteriorating. That is the moment the diagnosis should be reopened, not the moment the same plan should be pushed harder.
A word of balance
This is not a suggestion that most heart failure is misdiagnosed, because it is not, and the standard treatment helps enormously and saves lives every day. Amyloidosis and similar specific causes are comparatively rare, and not every case of heart failure needs a biopsy or a tertiary referral. The narrow, practical point is about what happens when optimised therapy fails. Progression despite correct treatment is the signal that the syndrome has an underlying driver worth chasing, and a specialised centre is where that chase belongs.
A medical second opinion is especially worth seeking when:
- Your heart failure keeps progressing despite full, optimised guideline treatment
- The label describes the problem (a weak or stiff heart) without ever naming its cause
- There are unusual features, such as a markedly thickened heart, drug intolerance, or a history of carpal tunnel syndrome
- You sense the plan is to keep adjusting the same medications rather than to ask why they are not working
Which leaves the question this case puts to every diagnosis that names a syndrome: when the label tells us what is happening but not why, have we actually done the work of finding the cause?
This is exactly the kind of situation CW1 is built for, helping patients obtain a medical second opinion when a treatment is not working, and strengthening the communication in healthcare that turns a syndrome into a true, treatable diagnosis.
Note: this is one case rather than medical advice, and no one should change or stop prescribed medication on their own. If this resonates, the right next step is a careful conversation with a cardiologist, ideally at a specialised centre.